Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
scientific article published on 27 September 2016
Author/s
author: Hagop Kantarjian, William G Wierda, Jorge Eduardo Cortes, Gautam Borthakur, Farhad Ravandi, Elias Jabbour, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Naveen Pemmaraju, Courtney D DiNardo, Naval Daver, Brittany Knick Ragon, Zhihong Zeng, Steven M Kornblau, Jan A Burger
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.